CRO ClinChoice has acquired CSI Medical Research, marking a significant expansion of its international operations.

The strategic move bolsters ClinChoice's full-service capabilities and footprint across more than 30 countries in Asia, Europe and North America.

CSI, established in 2017, is a Singapore-based clinical CRO providing new and cost-efficient clinical solutions.

It has a team of professionals and a network of partners across South East Asia (SEA), Australia and New Zealand (ANZ).

ClinChoice global chairman and CEO Ling Zhen stated: “This is an exciting time for ClinChoice, and we are thrilled to welcome the talented CSI team to the ClinChoice family.

“With their wide range of highly valuable service offerings and seasoned professional team, the acquisition of CSI will further expand our presence in SEA and ANZ and enhance our capability to well fulfil our clients' needs locally and globally.”

The acquisition comes at a time when the clinical research environment and infrastructure in South East Asia have seen considerable improvements.

CSI's expertise in regional practices, ethics, regulatory needs and site operations has positioned it as a prominent player in the domestic CRO landscape.

CSI medical research founder and CEO Nelson Wong stated: “We are excited to leverage our familiarity with the SEA and ANZ regulations as well as the clinical sites within a region we call home, to assist more customers to navigate through the challenges with great speed and better cost efficiencies.

“CSI's vision and mission in the approach to manage clinical trials are very much aligned with ClinChoice, and the company's high-quality, efficiency and teamwork culture will be fantastic for our talented employees and clients alike.”